Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Michael Matthay, MD

Description

Summary

This is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS). This study is the extension of the Phase 1 pilot study (NCT01775774) and Phase 2a study (NCT02097641).

Official Title

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome

Details

This clinical study design is a randomized, double-blinded, placebo-controlled Phase 2b clinical trial using a 10 million cell/kg dose of human Mesenchymal Stromal Cells (hMSCs). Subjects will be randomized in a 1:1 randomization scheme to receive hMSCs or cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) as the placebo; the study will enroll 120 patients who achieve a stable clinical baseline and receive study product (either hMSCs or the placebo).

The Data and Safety Monitoring Board (DSMB) will review adverse outcomes and protocol compliance. A pre-specified interim review will occur after 60 subjects have been enrolled and received study product; enrollment will continue during the DSMB review. All pre-specified clinically important events and unexpected serious adverse events including death during hospitalization up to 60 days will be reported to the DSMB on an ongoing basis; the study will be stopped for a safety evaluation by the DSMB if they have any concerns or if three subjects have pre-specified clinically important events or unexpected serious adverse events except death since death will be common in this critically ill population due the nature of the underlying illness (e.g., ARDS).

Keywords

Respiratory Distress Syndrome, Adult Human Mesenchymal Stromal Cells Acute Respiratory Distress Syndrome Syndrome Respiratory Distress Syndrome, Newborn Acute Lung Injury Dextrans Cell Reconstitution Media

Eligibility

You can join if…

Open to people ages 18 years and up

Patients will be eligible for inclusion if they meet all of the below criteria within 120 hours of initial ICU admission. Criteria 1-3 must all be present within a 24-hour time period and at the time of enrollment:

Acute onset (defined below) of:

  1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio <200 mmHg and ≥5 cm H2O positive end-expiratory airway pressure (PEEP), as per the Berlin Criteria.
  2. Bilateral infiltrates consistent with pulmonary edema (defined below) on the frontal chest radiograph, or bilateral ground glass opacities on a chest CT scan.
  3. No clinical evidence of left atrial hypertension as a primary explanation for the bilateral pulmonary infiltrates.
  4. If the cause of ARDS is trauma, additional inclusion criteria will include ONE of the following relevant risk factors for developing ARDS:
  5. Hypotension (systolic blood pressure[SBP] < 90 mmHg) in the field or in the first 24 h after injury, or
  6. Transfusion of 3 units of blood products in the first 24 hours following injury, or
  7. Meets the new Critical Administration Threshold (CAT) criteria with at least 3 units of blood in one hour, or
  8. Blunt or penetrating torso trauma, or
  9. Long bone fractures, or
  10. The highest level of institutional trauma activation

You CAN'T join if...

  1. Age less than 18 years
  2. Greater than 72 hours since first meeting ARDS criteria per the Berlin definition of ARDS
  3. Greater than 120 hours since initial ICU admission
  4. Inability to administer study product within 120 hours of ICU admission
  5. PaO2/FiO2 ≥ 200 mmHg after consent obtained and before study product is administered
  6. Unable to obtain informed consent/no surrogate available
  7. Pregnant or lactating
  8. In custody of law enforcement officials
  9. Burns > 20% of total body surface area
  10. . WHO Class III or IV pulmonary hypertension
  11. . History of cancer treatment in the last 2 years except for non-melanotic skin cancers
  12. . Underlying medical condition for which 6-month mortality is estimated to be > 50%
  13. . Moribund patient not expected to survive 24 hours
  14. . Advanced chronic liver disease (Childs-Pugh Score > 12)
  15. . Severe chronic respiratory disease with the use of home oxygen
  16. . Severe traumatic brain injury - defined as:
  17. A patient who has undergone intracranial neurosurgical intervention for monitoring or therapy (intracranial pressure monitoring, external ventricular drain, craniotomy), or
  18. Intracranial injury by head CT (does not include patients with minimal subarachnoid injury and/or minor skull fracture), or
  19. Post-resuscitation Glasgow Coma Score (GCS) < 9 assessed after sedation interruption, or
  20. Non-survivable head injury as assessed by neurosurgery
  21. . Evidence of anoxic brain injury
  22. . History of stroke within the last 3 years
  23. . No intent/unwillingness to follow lung protective ventilation strategy
  24. . Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory ventilation (HFOV)
  25. . Anticipated extubation within 24 hours of enrollment
  26. . Clinical evidence of left atrial hypertension as measured by a pulmonary arterial wedge pressure > 18mmHg or left ventricular failure measured by an echocardiogram with a left ventricular ejection fraction less than 40%. Clinical judgement will determine if either of these measurements needs to be carried out.

Locations

  • Zuckerberg San Francisco General Hospital and Trauma Center not yet accepting patients
    San Francisco California 94110 United States
  • University of California San Francisco not yet accepting patients
    San Francisco California 94143 United States

Lead Scientist

  • Michael Matthay, MD
    Dr. Matthay's overall focus is on improving clinical care of patients with acute respiratory failure from the acute respiratory distress syndrome and from sepsis. His research and clinical trials groups are very well funded by grants from the National Institute of Health. He also spends considerable time mentoring physicians and young faculty in career development and academic medicine.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Michael A. Matthay
ID
NCT03818854
Phase
Phase 2
Study Type
Interventional
Last Updated